Katie Ewer
From Wikipedia the free encyclopedia
Katie Ewer | |
|---|---|
| Academic background | |
| Education | PhD, Immunology, 2004, Open University |
| Thesis | Relationships between tuberculosis exposure, ex vivo antigen-specific T cell responses, and delayed type hypersensitivity in point-source outbreaks. (2004) |
| Academic work | |
| Institutions | University of Oxford |
Katie Jane Ewer is a British immunologist and Professor of Vaccine Immunology at the University of Oxford's Jenner Institute.[1]
Early life and education[edit]
When she did not get into medical school, Ewer pursued a career in biomedical science and became interested in infectious diseases.[2] She was interested in a career in biology for she was "fascinated by seemingly endless processes that occur in our cells and organs every second of our lives without us knowing about it.[3] Ewer earned an undergraduate degree in biomedical science, which included a year of microbiology training.[4] She then began working as a biomedical scientist at the microbiology department of the John Radcliffe Hospital in 2000,[5] before pursuing a PhD on the immunology of tuberculosis (TB).[4] Ewer earned her PhD at the Open University as a result of her research with Ajit Lalvani on novel diagnostic tools using T cells for the diagnosis of tuberculosis infection.[5]
Career[edit]
Upon earning her PhD, Ewer joined the UK's Animal and Plant Health Agency where she studied the effectiveness of TB vaccines in cattle and managed the roll-out of interferon-gamma-based diagnosis for bovine TB in the UK herd for the Department for Environment, Food and Rural Affairs.[5] While in this role, she co-published Diagnosis of tuberculosis in South African children with a T cell-based assay: a prospective cohort study with Susan Liebeschuetz.[6]
In 2008, Ewer became a Senior Immunologist at Oxford University's Edward Jenner Institute for Vaccine Research.[5] While there, she continued to study the effects of TB on populations and led clinical trials in an effort to discover a vaccine for Ebola.[7] The aim of her research was to define vaccine-induced immunological parameters that correlate with protection from malaria and understand why vaccines do not always work as well as expected.[8] During the COVID-19 pandemic, she led clinical controlled trials in an effort to find a vaccine, which was published in a 2020 study titled Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial.[9]
References[edit]
- ^ "Katie Ewer". www.jenner.ac.uk. Retrieved 2022-11-08.
- ^ Stokel-Walker, Chris (2020-04-10). "When Will There Be A Coronavirus Vaccine?". Esquire. Retrieved 2022-11-08.
- ^ Stokel-Walker, Chris (2020-04-10). "When Will There Be A Coronavirus Vaccine?". Esquire. Retrieved 2022-11-08.
- ^ a b Todd, Benjamin (20 November 2013). "Interview with malaria vaccine researcher Katie Ewer". 80000hours.org. Retrieved 21 July 2020.
- ^ a b c d "Katie Ewer". conted.ox.ac.uk. Retrieved 21 July 2020.
- ^ Susan Liebeschuetz; Sheila Bamber; Katie Ewer; Jonathan Deeks; Ansar A Pathan; Ajit Lalvani (1 December 2004). "Diagnosis of tuberculosis in South African children with a T-cell-based assay: a prospective cohort study". The Lancet. 364 (9452): 2196–2203. doi:10.1016/S0140-6736(04)17592-2. ISSN 0140-6736. PMID 15610806. S2CID 35679204. Wikidata Q46840144.
- ^ "Katie Ewer Senior Immunologist: Malaria and Ebola Vaccine Trials". ndm.ox.ac.uk. Archived from the original on 21 July 2020. Retrieved 21 July 2020.
- ^ "Katie Ewer ASSOCIATE PROFESSOR". medsci.ox.ac.uk. Retrieved 21 July 2020.
- ^ Pedro M Folegatti; Katie J Ewer; Parvinder K Aley; et al. (20 July 2020). "Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial". The Lancet. doi:10.1016/S0140-6736(20)31604-4. ISSN 0140-6736. PMC 7445431. PMID 32702298. Wikidata Q97678476.
External links[edit]
- Katie Ewer publications indexed by Google Scholar
